What are the primary revenue drivers for IDEXX Laboratories?

The primary revenue drivers for IDEXX Laboratories are its veterinary diagnostic products and services, which fall under the Companion Animal Group (CAG). This includes consumables for in-clinic diagnostic instruments, veterinary reference laboratory services, and test kits for various animal diseases and health conditions. The company also generates revenue from veterinary pharmaceuticals, practice management software, and, to a lesser extent, food and environmental testing products.

How did the divestiture of the food microbiology testing business impact the company's financial performance?

The divestiture of the food microbiology testing business, completed in late 1999 and early 2000, resulted in a decrease in revenue for the Food and Environmental Division (FED). However, it positively impacted FED's gross margin percentage. This was because the divested business had lower gross margins, and the remaining FED business, particularly water and dairy testing, has higher margins, leading to an overall improvement in profitability for that segment.

What is the company's strategy for future growth and innovation?

IDEXX Laboratories focuses its growth strategy on continued innovation through substantial investment in research and development. This includes developing new diagnostic tests and systems, enhancing its veterinary practice management software and internet services, and expanding its portfolio of veterinary pharmaceuticals. Strategic acquisitions are also a key component of its growth strategy, as seen with the recent acquisitions of veterinary reference laboratories and companies in the water testing sector.

What is the company's stance on paying dividends?

IDEXX Laboratories has never paid cash dividends on its Common Stock and does not anticipate paying any in the foreseeable future. The company intends to reinvest future earnings to fund the development and growth of its business.

IDXX 10-K FY2000 Annual Report — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) presents its 2000 Form 10-K, detailing robust performance primarily driven by its Companion Animal Group (CAG). CAG, encompassing veterinary diagnostics, pharmaceuticals, and informatics, saw revenue growth fueled by increased reference laboratory services, consumables, and test kits. Despite a slight dip in gross margin percentage due to a higher mix of lower-margin services, overall operating expenses remained controlled, largely due to strategic expense management and the ongoing development of its internet platform for animal health professionals. The Food and Environmental Division (FED) experienced a revenue decline, primarily attributed to the divestiture of its food microbiology testing business. However, gross margins within FED improved significantly due to the disposal of the lower-margin business and growth in higher-margin water testing products. The company continues to invest in research and development, focusing on new diagnostic systems, enhanced information solutions, and novel veterinary therapeutics, positioning itself for future growth and innovation in the animal health sector.

Key Highlights

1IDEXX Laboratories' core business, the Companion Animal Group (CAG), demonstrated solid revenue growth of 6% in 2000, driven by increases in reference laboratory services, consumables, and test kits.

2The company successfully managed operating expenses, with CAG's operating expenses remaining stable as a percentage of revenue (34%), despite investments in new product development and its internet platform.

3The divestiture of the food microbiology testing business led to a revenue decrease in the Food and Environmental Division (FED), but improved FED's gross margin percentage due to the shift towards higher-margin water testing products.

4Significant investments in research and development ($28.3 million in 2000) are focused on enhancing existing diagnostic systems, developing new test kits, and advancing veterinary therapeutics and information solutions.

5The company is actively pursuing strategic acquisitions, with several acquisitions in veterinary reference laboratories and water testing products completed in 1999 and 2000.

6IDEXX Laboratories continues its share repurchase program, buying back 3.1 million shares in 2000 for $70.3 million, demonstrating a commitment to returning value to shareholders.

7The company anticipates future growth, with new product introductions planned for 2001, including the Lasercyte hematology system and a computed radiography instrument for the veterinary market.

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2000

Summary

Key Highlights

Frequently Asked Questions